The Singapore Immunology Network (SIgN) was launched on 10 February 2006 by the Agency for Science, Technology and Research (A*STAR) with the aim of expanding and strengthening immunology research in Singapore. In January 2008, 6000m2 of new laboratory and office space was inaugurated as the home of SIgN, in the Immunos building at Biopolis.
The mandate of SIgN is to advance human immunology research and participate in international efforts to combat major health problems. Researchers at SIgN investigate immunity during infections and inflammatory conditions, including cancer, using both mouse models and human tissues.
Since its launch SIgN has grown rapidly, and currently includes around 200 scientists from 25 different countries of the world, working under 21 renowned Principal Investigators. Scientists' work is supported by cutting edge technological research platforms and core services.
View SIgN's Corporate Brochure 2016